New York, NY (January 7, 2013) The Damon Runyon Cancer Research Foundation announced that seven scientists with novel approaches to fighting cancer have been named 2013 recipients of the Damon Runyon-Rachleff Innovation Award. The grant of $450,000 over three years is awarded each year to early career scientists whose projects have the potential to significantly impact the prevention, diagnosis and treatment of cancer.
Funding Daring Research
The Damon Runyon-Rachleff Innovation Award funds cancer research by exceptionally creative thinkers with "high-risk/high-reward" ideas who lack sufficient preliminary data to obtain traditional funding. The awardees are selected through a highly competitive and rigorous process by a scientific committee comprised of leading cancer researchers who are innovators themselves. At the final stage of selection, candidates are screened by an in-person interview with committee members. Only those scientists with a strong vision and passion for curing cancer are selected to receive the prestigious award.
This program is possible through the generous support of Andy and Debbie Rachleff, the Island Outreach Foundation and Nadia's Gift Foundation.
2013 Damon Runyon-Rachleff Innovators:
Michael Z. Lin, MD, PhD
Stanford University, California
Currently available cancer treatments, such as chemotherapeutics, targeted inhibitors or immunotherapies, are not capable of fully eradicating cancers and are limited by toxicities and side effects.
Dr. Lin aims to take a new approach to cancer treatment by engineering a virus that will infect and replicate specifically in cancer cells, triggering their destruction. This strategy aims not to suppress oncogenic signaling, but to use it as a trigger for a smart biological therapy. If he succeeds, progress will be made toward developing a much-needed "magic bullet" against cancer.
Christine Ma
'/>"/>
| Contact: Yung S. Lie, Ph.D. yung.lie@damonrunyon.org 212-455-0521 Damon Runyon Cancer Research Foundation Source:Eurekalert |